Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Antibodies for the treatment of MDS: magrolimab & sabatolimab

Guillermo Garcia-Manero • 10 Jun 2022
EHA 2022
Myelodysplastic Syndromes Antibodies Azacitidine Magrolimab Sabatolimab
ENHANCE STIMULUS-MDS1 STIMULUS-MDS2

Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses up-and-coming antibodies under investigation for the treatment of myelodysplastic syndromes (MDS) in the first-line setting, highlighting key clinical trials. Dr Garcia-Manero comments on magrolimab, which is currenly being evaluating in the ENHANCE trial (NCT04313881), and sabatolimab, which is under investigation in the STIMULUS-MDS1 (NCT03946670) and STIMULUS-MDS2 (NCT04266301) studies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Guillermo Garcia-Manero

3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Cytogenetic and molecular associations with outcomes in HR-MDS treated with HMAs plus venetoclax
Guillermo Garcia-Manero • 9 Apr 2024

Related Videos

2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals